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Abstract
Background: Our microbial companions (the “microbiota”) are extremely important for the preservation of human
health. Although changes in bacterial communities (dysbiosis) are commonly associated with disease, such changes
have also been described in healthy pregnancies, where the microbiome plays an essential role in maternal and child
health outcomes, including normal immune and metabolic function in later life. Nevertheless, this new understanding
of the importance of the microbiome has not yet influenced contemporary clinical practice regarding antibiotic use
during pregnancy.
Discussion: Antibiotic treatment during pregnancy is widespread in Western countries, and accounts for 80 % of
prescribed medications in pregnancy. However, antibiotic treatment, while at times lifesaving, can also have detrimental
consequences. A single course of antibiotics perturbs bacterial communities, with evidence that the microbial ecosystem
does not return completely to baseline following treatment. Antibiotics in pregnancy should be used only when
indicated, choosing those with the narrowest range possible.
Summary: Bacteria are essential for normal human development and, while antibiotic treatment during pregnancy
has an important role in controlling and preventing infections, it may have undesired effects regarding the maternal
and fetoplacental microbiomes. We expect that microbiota manipulation in pregnancy, through the use of probiotics
and fecal microbiota transplantation, will be the subject of increasing clinical interest.
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Background
The human body is home to a variety of microorganisms,
termed the microbiota, consisting of up to 100 trillion
bacterial cells, most of which reside in the gut. Large
sequencing efforts, such as the Human Microbiome
Project, have characterized the microbiota of the major
sites (gut, mouth, skin, airways, and vagina) of the hu-
man body in healthy individuals and demonstrated that
different body sites harbor diverse populations of microbes
[1]. Our microbial companions are extremely important
for the preservation of human health, and a growing num-
ber of studies describe how changes in these bacterial
communities are linked to disease states such as obesity
[2], diabetes [3], atherosclerosis [4], and autoimmune dis-
orders [5], among others. These shifts in community struc-
ture are termed dysbiosis. Although dysbiosis is commonly
associated with disease, it has also been described in healthy
pregnancies in which there is a bidirectional relationship
between pregnancy and the microbiome, whereby preg-
nancy affects the composition of the microbiome and the
microbiome plays a role in maternal and child health out-
comes [4]. These shifts in microbial composition occur in
several sites in the body of the pregnant woman.
Maternal gut and vaginal microbiome changes
during normal pregnancy and pregnancy
complications
Pregnancy is characterized by profound hormonal, im-
munological, and metabolic changes aimed at supporting
the growth of the fetoplacental unit [6]. Interestingly, a
healthy pregnancy also induces dramatic changes in the
maternal gut microbiota over the course of gestation,
with a great expansion of diversity between individuals,
an overall increase in Proteobacteria and Actinobacteria,
and reduced diversity within each microbiome. Similarly,
the vaginal microbiome in pregnancy is different from that
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of non-pregnant women, with lesser diversity and rich-
ness, and with a dominance of Lactobacillus species, Clos-
tridiales, Bacteroidales, and Actinomycetales [7]. When
transferred to germ-free mice, third trimester microbiota
induced greater adiposity and low-grade inflammation
compared to first trimester microbiota [4], and it was
recently suggested that alteration of the gut microbiota
during pregnancy may also induce complications of
pregnancy such as excessive maternal weight gain [8].
Maternal pregnancy complications significantly influence
the bacterial composition and diversity of the stool micro-
biota of premature infants, with these changes persisting
during the first year after birth [9]. Antibiotic usage during
pregnancy undoubtedly affects the bacterial environment of
the mother and of the fetus.
Bacteria of the fetoplacental unit – more fact than
fiction?
We are rapidly progressing towards understanding the role
of bacteria in novel target organs traditionally considered
“sterile”, including the central nervous system [10], blood
[11], the lower airways [12], the sub-epidermis [13], and the
fetoplacental unit [14]. ‘The fetus lies in a sterile environ-
ment’ declared the French pediatrician Henry Tissier of the
Pasteur Institute in 1900 [15]; since then, the placenta was
traditionally believed to form a sterile barrier between the
colonized maternal urogenital tract and the fetus. However,
recent studies have challenged this assumption. The first
demonstration of bacteria in the placenta in the modern
scientific literature was published in 1982 by Kovalovszki et
al. [16]. Subsequent publications have described the placen-
tal microbiome, using culture-dependent and -independent
methods, and suggested its relative similarity to the oral
microbiome, with bacteria such as Prevotella tannerae
and Neisseria being present in the placenta [14] (Fig. 1).
Specific components of the placental microbiome have
been linked to particular pregnancy complications
(Table 1, Fig. 2). Several mechanisms of amniotic fluid
colonization have been proposed, including the transloca-




















Enterococcus [74]  
Fig. 1 The fetoplacental microbiome of healthy pregnancy and its origins. Bacteria and their genes have been isolated from human placentas, amniotic
fluid, fetal membranes, and fetal gastrointestinal tract in healthy, normal pregnancies. These bacteria have three main routes of entry: the oro-fetoplacental
route, the gastrointestinal-fetoplacental route, and the genitourinary-fetoplacental route. Examples of specific bacteria are indicated
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the oral cavity [18]. Other possible routes include
hematogenous spread or bacterial migration from the
lower gastrointestinal tract to the lower genitourinary
tract (Fig. 1).
The fetal membranes consist of the amniotic membrane,
which contains the amniotic fluid, and the chorion, which
is in proximity with the decidua parietalis. It has been
shown that certain bacteria may be present in fetal mem-
branes without leading to an inflammatory response [16];
Galask et al. [19] demonstrated that bacteria can traverse
intact fetal membranes. Other bacteria resident in the fetal
membranes are thought to play a role in amniotic inflam-
mation, and thus in the initiation of labor [20].
Some of the studies described above demonstrated very
low levels of bacterial DNA in the fetoplacental compo-
nents. As detection methods become more sensitive, even
more rigorous precautions must be taken against con-
tamination when screening for bacterial colonization
[21]. Nevertheless, despite the possibility of sample con-
tamination, the physiological and beneficial presence of
bacteria in the placenta is gaining widespread acceptance.
Antibiotic use in pregnancy - an opinion
Perhaps the most clinically relevant aspect of the pregnancy
microbiome is antibiotic treatment during pregnancy. Anti-
biotics account for 80 % of all prescribed medication in
pregnancy [22], yet surprisingly, few published human
studies have carefully evaluated the direct effects of
antibiotics during pregnancy on either the maternal or
fetal microbiome, or evaluated long-term sequelae of such
antibiotic use. Thus, there may be a reason for caution in
prescribing antibiotics during pregnancy.
In pregnant NOD mice, antibiotic treatment caused
alteration of gut microbiota and immunological changes
in the intestine of the offspring [23]. In pregnant women,
it was demonstrated that antibiotic administration during
pregnancy leads to alterations in the vaginal microbiome
prior to birth, with long-term effects on the early micro-
bial colonization of the newborn [24] and an association
with childhood obesity [25].
There are several components to this issue. Antibiotic
treatment of infectious diseases is one of the greatest ad-
vances of modern medicine. Accordingly, antibiotics are
widely prescribed during pregnancy as the most import-
ant modality for treating and preventing infections. It is
estimated that one in five pregnant women in Europe is
prescribed at least one antibiotic during pregnancy; in
the United States, the rate is double [26]. Nevertheless,
prescription of antibiotics should be carefully considered
on an individual basis, weighing its benefits versus draw-
backs for both the fetus and the mother. It has been
shown that administration of certain antibiotics is linked
to a significantly higher rate of neonatal necrotizing entero-
colitis, although antibiotic treatment is also associated with
a reduced rate of lung complications and major cerebral ab-
normalities, relative to non-antibiotic treated controls [27].
A more recent study published in 2008 demonstrated that
the prescription of antibiotics for women in spontaneous
preterm labor with intact membranes was associated with
an increased risk of cerebral palsy and functional impair-
ment among their children at 7 years of age [28].
As discussed above, the healthy microbiome is important
for maintaining a normal pregnancy and, therefore, it has
been suggested that we may be using too many antibiotics
during pregnancy [29]. A large systematic review con-
cluded that antibiotics during the second and third tri-
mester do not reduce adverse pregnancy outcomes and
morbidity [30]. In addition, even a short course of anti-
biotics perturbs bacterial communities in human hosts
[30]. In one study, it was shown that, within 30 days
following cessation of antibiotic treatment, fecal micro-
biota reached an average similarity of 88 % to baseline,
with the level rising to 89 % within 60 days [31];
Table 1 Summary of studies providing evidence for bacteria in the human fetoplacental unit in both complicated and
uncomplicated pregnancies (✓marks published evidence)
Pregnancy state Method Placenta Amniotic fluid Fetal membranes Reference
Normal pregnancy Microscopy ✓ ✓ ✓ [26, 37–40]
Bacterial cultures ✓ ✓ ✓ [16, 37, 39, 41–50]
Culture independent methods ✓ ✓ ✓ [14, 26, 37, 38, 41, 43, 45, 50–62]
Premature rupture of membranes
and preterm labor
Microscopy ✓ ✓ [41, 61]
Bacterial cultures ✓ ✓ [16, 20, 39, 44, 50, 52, 57, 63–69]
Culture independent methods ✓ ✓ ✓ [14, 16, 19, 20, 39, 42, 46, 50,
52, 53, 61, 70]
Intrauterine growth restriction Bacterial cultures ✓ [71]
Culture independent methods ✓ [45, 72]
Pre-eclampsia Bacterial cultures ✓ ✓ [46, 72, 73]
Culture independent methods ✓ ✓ [49, 51, 58, 62, 72, 73]
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however, the microbiota did not completely return to
baseline over the timescale studied. Thus, antibiotics cause
an immediate perturbation of the ecosystem, followed by
incomplete recovery of the gut microbiome. The response
to a given antibiotic is individualized, and may be influ-
enced by prior exposure to the same drug. Accordingly,
even a short course of antibiotics may sometimes have a
long lasting residual effect on the microbiome, with pos-
sible metabolic or immune consequences.
The use of antibiotics during pregnancy has also been
associated with increased risk of asthma in early child-
hood [32–34], increased risk of childhood epilepsy, and
increased risk of childhood obesity [25]. Of course, the
argument could be made that the primary maternal in-
fection was the cause for the increased risk of these con-
ditions, rather than the treatment itself. Nevertheless, we
suggest that antibiotics in pregnancy may affect the bac-
terial ecosystem of the mother as well as that of the
A. Premature labor / premature rupture of membranes
C. Preeclampsia
























Fig. 2 The fetoplacental microbiome in various pregnancy complications involving the placenta. Examples of specific disease-associated species
are shown. a Bacteria are found in the placenta (Streptococcus avermitilis), fetal membranes (Fusobacterium nucleatum), and amniotic fluid
(Ureaplasma parvum) in cases of premature labor and premature rupture of membranes. b Bacteria are present in amniotic fluid (Mycoplasma
hominis) in small-for-gestational-age (intrauterine growth restriction) fetuses. c Bacteria are present in the placenta (Gardnerella vaginalis) and
amniotic fluid (Sneathia/Leptotrichia spp) in cases of preeclampsia. A pregnant woman is illustrated, exhibiting headache, edema, and petechia
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fetus, and therefore that their use should be carefully
considered based on what is known, and what remains
unknown, regarding their effects.
Recent studies have demonstrated that priming of the
immune system and microbiota-driven immune changes
begin in utero and are not – as traditionally believed –
induced postnatally by the newborn’s microbiota [35].
These new insights suggest that the maternal microbiota
during pregnancy actually drives early postnatal innate
immune development [36]. It is becoming clearer that
the maternal microbiota, in concert with maternal anti-
bodies, are important in preparing the fetus for host-
microbial symbiosis later in life. The mechanisms of this
phenomenon are now being explored and involve micro-
bial molecular transfer (without any live bacteria). In
addition, maternal antibodies have a dual effect, promot-
ing pathogen neutralization whilst simultaneously en-
hancing microbial molecular transfer. Gomez de Aguero
et al. [36] recently showed that pups of mothers transi-
ently colonized during pregnancy have a greater capacity
to avoid inflammation in response to bacterial molecules
and penetration of intestinal microbes. Thus, the maternal
microbiota plays a role in shaping the postnatal immune
system and interferences with maternal microbiota during
pregnancy may hinder the natural process of prenatal im-
mune priming.
We believe that the issue of antibiotics during preg-
nancy is one of the greatest challenges of human micro-
biome research and certainly deserves increased focus in
the form of observational and interventional studies to
unravel the role of these drugs in human development.
Summary and future directions
One may argue for the importance of antibiotics during
pregnancy to prevent or treat bacterial infections. Indeed,
antibiotics have an important role in improving and pro-
moting health in pregnant women. Nevertheless, as with
other therapeutic modalities, overuse may be counter-
productive. The realization that antibiotic use in pregnancy
may interfere with the delicate balance between the preg-
nant woman’s microbiota, which is important for normal
fetal development, may gradually decrease the enormous,
and possibly excessive, utilization of these drugs during
pregnancy. In case of proven maternal infection, narrow
spectrum antibiotics should be preferred due to their less
extensive effects on the microbiome, taking into account
the association of prenatal antibiotics with increased risk of
childhood asthma, epilepsy, and obesity. Future studies
should focus on maternal microbiome manipulations such
as personalized probiotics and fecal microbiota transplant-
ation, and their effect on pregnancy outcome, as well as on
the use of specific microbial profiling for diagnosis of preg-
nancy complications and prediction of long-term outcomes
of newborn and maternal health.
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